Breakthrough in Heart Health: CardiAMP Cell Therapy’s Phase 3 Trial Launches
BioCardia, a pioneer in cellular therapeutics, has announced the commencement of patient enrollment for its pivotal Phase 3 trial of the CardiAMP Cell Therapy for the treatment of ischemic heart failure with reduced ejection fraction (HFrEF). This marks a significant milestone in advancing innovative treatments for cardiovascular diseases. Key Highlights: Expert Endorsements: Dr. Leslie Miller, […]
BioCardia Announces FDA Approval for Groundbreaking Heart Failure Treatment
BioCardia, Inc., a prominent player in the development of cellular and cell-derived therapeutics for cardiovascular and pulmonary diseases, has recently announced a significant milestone. The U.S. Food and Drug Administration (FDA) has approved the Phase III clinical trial protocol for BioCardia’s CardiAMP autologous cell therapy. This therapy is designed for patients suffering from ischemic heart […]